Specific anti-tumor effect induced by attenuated Salmonella typhimurium vaccine expressing extracellular region of vascular endothelial growth factor receptor 2

被引:0
作者
YANG Jun1
2 Biotherapy Center
3 Department of Pathology
机构
关键词
attenuated Salmonella typhimurium; vector; vascular endothelial growth factor receptor 2; gene therapy;
D O I
暂无
中图分类号
R392.1 [免疫生物学];
学科分类号
100102 ;
摘要
The purposes of this research were to study the stable expression of exogenous gene encoding therapeutic protein in attenuated Salmonella typhimurium, observe the metabolism of oral gene vaccine carried by attenuated Salmonella typhimurium in BALB/c mouse, and investigate the feasibility of prevention and treatment of tumors by the recombinant bacteria. Recombinant plasmid pcDNA3.1+ VEGFR2(n1-7) was transformed into competent attenuated Salmonella typhimurium SL3261 to develop oral DNA vaccine SL3261-pcDNA3.1+VEGFR2(n1-7). To observe whether the exogenous gene can be expressed in the recombinant bacteria, PCR was performed to amplify the CMV promoter of the eukaryotic expression vector as the proof of stable expression of exogenous protein; transmission elec- tron microscopy (TEM) was applied to observe the morphology of the recombinant bacteria to confirm that the exogenous gene has no impact on the growth of the bacteria, and then BALB/c mice were immunized with the gene vaccine. After inoculation of the gene vaccine, the recombinant bacteria SL3261 could be detected in the tissues such as small intestine, colon, liver and spleen. And then, mice in each group were challenged with tumor cells. The results of animal experiment showed that tumor growth of the mice in experimental group was inhibited and survival time of immunized mice was prolonged compared with control groups. A higher lymphocyte infiltration in tumors from animals treated with DNA vaccine was observed. Immunohistochemical analysis of tumor samples revealed an en- hanced accumulation of CD8+ cytotoxic T lymphocytes, as well as an increase in CD4+ cells in the tumors of animals treated with the oral gene vaccine compared to tumors from control group mice. Ultrastructure of the tumor tissue showed that tumor cells in the samples of the immunized mice were well-differentiated. Our research confirmed that the exogenous gene can be stably expressed in the attenuated Salmonella typhimurium and has no impact on the growth of the recombinant bacteria; the exogenous gene can de delivered to the host by attenuated Salmonella typhimurium to produce anti-tumor effect with no obvious cytotoxity to the host. In this study, it is established that attenuated Salmonella typhimurium could be used as a vector for oral gene vaccine, and our study provided a theoretical basis for the body distribution and the metabolism of the recombinant bacteria. This strategy may provide a simple, safe and effective way for the prevention and treatment of tumors.
引用
收藏
页码:3000 / 3007
页数:8
相关论文
共 8 条
  • [1] Specific anti-tumor effect induced by attenuated Salmonella typhimurium vaccine expressing extracellular region of vascular endothelial growth factor receptor 2
    Yang Jun
    Dong Jian
    Pu Ping
    Wang ZhiQiang
    Hong Min
    Chen MingQing
    CHINESE SCIENCE BULLETIN, 2008, 53 (19): : 3000 - 3007
  • [2] Anti-tumor angiogenesis therapy using soluble receptors: enhanced inhibition of tumor growth when soluble fibroblast growth factor receptor-1 is used with soluble vascular endothelial growth factor receptor
    Tadashi Ogawa
    Koichi Takayama
    Nobuyuki Takakura
    Seigo Kitano
    Hikaru Ueno
    Cancer Gene Therapy, 2002, 9 : 633 - 640
  • [3] Anti-tumor angiogenesis therapy using soluble receptors: enhanced inhibition of tumor growth when soluble fibroblast growth factor receptor-1 is used with soluble vascular endothelial growth factor receptor
    Ogawa, T
    Takayama, K
    Takakura, N
    Kitano, S
    Ueno, H
    CANCER GENE THERAPY, 2002, 9 (08) : 633 - 640
  • [4] Attenuated Salmonella typhimurium containing interleukin-2 decreases MC-38 hepatic metastases: A novel anti-tumor agent
    Saltzman, DA
    Heise, CP
    Hasz, DE
    Zebede, M
    Kelly, SM
    Curtiss, R
    Leonard, AS
    Anderson, PM
    CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS, 1996, 11 (02) : 145 - 153
  • [5] Evaluation of a xenogeneic vascular endothelial growth factor-2 vaccine in two preclinical metastatic tumor models in mice
    Denies, Sofie
    Leyman, Bregje
    Huysmans, Hanne
    Combes, Francis
    Mc Cafferty, Sean
    Cicchelero, Laetitia
    Steppe, Marjan
    De Temmerman, Joyca
    Sanders, Niek N.
    CANCER IMMUNOLOGY IMMUNOTHERAPY, 2017, 66 (12) : 1545 - 1555
  • [6] Enhancement of DNA vaccine efficacy by targeting the xenogeneic human chorionic gonadotropin, survivin and vascular endothelial growth factor receptor 2 combined tumor antigen to the major histocompatibility complex class II pathway
    Wei, Yuying
    Sun, Yuanjie
    Song, Chaojun
    Li, Haitao
    Li, Yongming
    Zhang, Kui
    Gong, Jiuyu
    Liu, Fei
    Liu, Zhijia
    August, J. T.
    Jin, Boquan
    Yang, Kun
    JOURNAL OF GENE MEDICINE, 2012, 14 (05) : 353 - 362
  • [7] Effect of oral hepatocyte growth factor gene mediated by attenuated salmonella on 2-, 4-, 6-trinitro-benzene-sulfonic-acid-induced ulcerative colitis in rat
    Ha, Xiaoqin
    Yin, Qiang
    Hui, Ling
    Jia, Qinghua
    Wang, Meiliang
    Zhang, Junli
    Xu, Yuebin
    Chang, Yewei
    Yang, Xiaopeng
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2012, 27 (03) : 609 - 615
  • [8] Surface display of vascular endothelial growth factor receptor-2 specific nanobody on 293T cells - A potential targeting moiety for lentiviral vector-based cancer therapy
    Ahani, Roshank
    Roohvand, Farzin
    Mohajel, Nasir
    Etemadzadeh, Mohammad Hossein
    Behdani, Mehdi
    Shahosseini, Zahra
    Azadmanesh, Kayhan
    ROMANIAN BIOTECHNOLOGICAL LETTERS, 2016, 21 (05): : 11816 - 11824